Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 16 min ago
Peer-reviewedCC BY-NC-NDActa pharmaceutica Sinica. B

Lysosome-targeted nanomaterials for advanced cancer therapy: Overcoming resistance, activating immunity and amplifying therapeutic synergy.

  • Hongmei Zheng1,2
  • Haipeng Cheng1,2
  • Namei Li1,2
  • Jing Cai1,2
  1. 1Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  2. 2Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis, Changsha 410011, China.
Read full textPDFDOICite

Abstract

Lysosomes were once regarded merely as the cellular "waste disposal" system, but are now widely recognized as pivotal hubs for regulating intracellular homeostasis and have emerged as promising therapeutic targets in cancer treatment. This review systematically explores the interplay between nanomaterials and lysosomal function, focusing particularly on how to leverage this interaction to enhance antitumor efficacy. First, we outline the mechanisms by which nanomaterials modulate lysosomal activity. Next, we review the main antitumor pathways used by lysosome-targeted nanomaterials, such as inhibiting autophagic flux, activating programmed cell death pathways (including cuproptosis, ferroptosis, apoptosis, and pyroptosis), and remodeling the immunosuppressive tumor microenvironment. We also analyze various strategies for synergistic enhancement, such as metabolic intervention and stimuli-responsive combination therapies (such as light-, ultrasound- or ROS-activated), as well as lysosome-targeted approaches for improving conventional chemotherapy and radiotherapy. In conclusion, this review provides a comprehensive overview of current lysosome-targeted nanomedicine research and outlines future directions for translating these strategies into clinical applications.

Related

  1. NEURL1-mediated K63-ubiquitination of SLC40A1 drives ferroptosis resistance in pathological scars: Therapeutic targeting via autophagy-activating microneedles.
    Mengzhu Lv, Jiamei Liu, Qi Dong +4
    Redox biologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  2. Extrachromosomal DNA: A New Therapeutic Frontier for Overcoming Cancer Drug Resistance
    Dooil Jeoung
    CellsPeer-reviewedCC BY 4.0Full textGenetics & genomicsCrossrefEurope PMCDOAJ
  3. Editorial: Mechanisms of drug resistance in cancer: overcoming barriers with novel pharmacological strategies
    Pulak Kar, Donato Colangelo, Maushmi Shailesh Kumar +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Discovery of a Virulent Population of Meloidogyne graminicola Overcoming the Rice Resistance Gene MG1 and Population Genetic Analysis Based on mtCOI Sequences
    Ao Xu, Borong Lin, Qiuling Huang +4
    Plants (Basel, Switzerland)Peer-reviewedCC BYFull textPlant biologyEurope PMC
  5. The Potential Therapeutic Effect of Nanomaterials on Central Nervous System Disorders
    Xiaotong Shao, Zhengyi Li, Jie Zhu +3
    International Journal of NanomedicinePeer-reviewedCC BY-NC 4.0Full textMaterials & polymersPMC

Cite

BibTeXRIS
BibTeX
@article{zheng2026lysosometargeted,
  title = {{Lysosome-targeted nanomaterials for advanced cancer therapy: Overcoming resistance, activating immunity and amplifying therapeutic synergy.}},
  author = {Hongmei Zheng and Haipeng Cheng and Namei Li and Jing Cai},
  journal = {Acta pharmaceutica Sinica. B},
  year = {2026},
  month = aug,
  doi = {10.1016/j.apsb.2026.08.005},
  url = {https://europepmc.org/article/MED/42948768},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Lysosome-targeted nanomaterials for advanced cancer therapy: Overcoming resistance, activating immunity and amplifying therapeutic synergy.
AU  - Hongmei Zheng
AU  - Haipeng Cheng
AU  - Namei Li
AU  - Jing Cai
PY  - 2026
DA  - 2026/08/08
JO  - Acta pharmaceutica Sinica. B
DO  - 10.1016/j.apsb.2026.08.005
UR  - https://europepmc.org/article/MED/42948768
AB  - Lysosomes were once regarded merely as the cellular "waste disposal" system, but are now widely recognized as pivotal hubs for regulating intracellular homeostasis and have emerged as promising therapeutic targets in cancer treatment. This review systematically explores the interplay between nanomaterials and lysosomal function, focusing particularly on how to leverage this interaction to enhance antitumor efficacy. First, we outline the mechanisms by which nanomaterials modulate lysosomal activity. Next, we review the main antitumor pathways used by lysosome-targeted nanomaterials, such as inhibiting autophagic flux, activating programmed cell death pathways (including cuproptosis, ferroptosis, apoptosis, and pyroptosis), and remodeling the immunosuppressive tumor microenvironment. We also analyze various strategies for synergistic enhancement, such as metabolic intervention and stimuli-responsive combination therapies (such as light-, ultrasound- or ROS-activated), as well as lysosome-targeted approaches for improving conventional chemotherapy and radiotherapy. In conclusion, this review provides a comprehensive overview of current lysosome-targeted nanomedicine research and outlines future directions for translating these strategies into clinical applications.
SN  - 2211-3835
SN  - 2211-3843
ER  -